Is Nucor (NUE) a risky stock?
As of July 21, 2026, Clavix grades Nucor (NUE) B+ for risk, a composite score of 81 out of 100 on an A+ to F scale, which puts NUE in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind NUE's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how NUE scores on each, as of July 21, 2026.
What's moving NUE's risk right now
Company-specific signals Clavix flags behind NUE's current grade, drawn from recent news and filings as of July 21, 2026.
Bank of America lowered its Nucor price target to $280 but kept its buy rating, meaning analysts still see upside. Hedge funds like Slate Path Capital have been adding shares, and some write-ups call the stock undervalued given strong cash flow.
Nucor filed an 8-K on July 20, 2026 and will hold its Q2 earnings call with CEO Leon Topalian. The stock has kept pace with materials peers like Teck Resources this year, putting the spotlight on the upcoming results.
What a B+ grade means
On the Clavix A+ to F scale, NUE's composite of 81 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell NUE or any security. Grades are risk indicators, not predictions of return. Data may be delayed.